Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies Academic Article uri icon

Overview

MeSH Major

  • Drug Resistance, Neoplasm
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, B-Cell
  • Neoplasm Recurrence, Local
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Pyrazoles
  • Pyrimidines

abstract

  • Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.

publication date

  • January 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5505166

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.42.7906

PubMed ID

  • 23045577

Additional Document Info

start page

  • 88

end page

  • 94

volume

  • 31

number

  • 1